'Manufactures of Medicines of Ukraine' Association's Chairman: No government support for Ukrainian exports

Chairman of the Association "Manufactures of Medicines of Ukraine" (AMMU) Petro Bahriy told Interfax-Ukraine how the pharmaceutical industry operates and what manufacturers face in international markets

Interviewed by Anna Levchenko

- How do you assess the work of the pharmaceutical industry in 2023? Has the industry survived?

- The Ukrainian market of medicines amounted to UAH 130 billion in 2023. In money terms, this is an increase of 25%, year-over-year in the Ukrainian currency (UAH) or an increase of 9.4% in U.S. dollars. Thus, the pharmaceutical market in 2023 was $3.5 billion more than in 2022. In physical terms (packages), market indicators in 2023 increased by 0.5%, year-over-year, to 848 million, that is, both in packages and in money, we did not reach the pre-war level. But an annual growth of 25% in hryvnia is a significant increase in sales.

In terms of domestic medicines and imports, 63.1% of the market in packages are domestically manufactured medicines. This trend remains almost unchanged. In monetary terms, some 37.9% of the market in dollars is domestic medicines. This trend also remains unchanged and at almost the same level as in the pre-war period.

It is worth noting that in 2023 the market has relatively stabilized, the population has more or less returned, and demand has stabilized.

- What about the assortment? Has it changed?

- It the relation to the assortment, in 2023 the increase occurred in all groups of medicines and in all nosology forms. The top sellers are primarily analgesics and non-steroidal anti-inflammatory medicines, including Nimesulide and Nurofen.

Among companies, domestic ones occupy the first place in the market. This is pleasing to me both as AMMU chairman and as a